20.06.2024 11:00:07 - dpa-AFX: GNW-Adhoc: ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth
* With a significant track record of success in the radiopharmaceutical
industry, Dr. Cavey will help accelerate ITM's pipeline and business growth
Garching / Munich, Germany, June 20, 2024 - ITM Isotope Technologies Munich SE
(ITM) (https://itm-radiopharma.com/home), a leading radiopharmaceutical biotech
company today announced the appointment of Dr. Andrew Cavey, as its Chief
Executive Officer effective September 1, 2024. ITM's current CEO, Steffen
Schuster, will step up to the company's Supervisory Board.
"The strength of ITM is our ability to deliver radiopharmaceutical innovation.
With his strong global background in clinical practice, strategy, clinical
development, and commercialization, we are confident that Andrew is the right
choice to lead ITM throughout our next growth phase," said Udo J. Vetter,
Chairman of the Supervisory Board of ITM. "I would like to thank Steffen for his
dedication and leadership over the last twelve years. His impact on the
company's growth and development cannot be understated. I am delighted that we
will continue to benefit from his expertise and I welcome him to the Supervisory
Board."
Dr. Cavey will work together with ITM's leadership team to spearhead the next
stages of growth as the company broadens and advances its targeted
radiopharmaceutical pipeline and expands its industry-leading medical
radioisotope manufacturing capabilities. He joins ITM with a career spanning
clinical development, corporate strategy and commercial management across
international biotech and radiopharmaceutical companies including Bristol Myers
Squibb (BMS) and Novartis.
"The ITM team has created an impressive organization. Today the company is a
cornerstone of the radiopharmaceutical industry, with its supply of high-quality
medical radioisotopes and its broad pipeline of innovative radiopharmaceutical
medicines across cancer indications, including its lead program ITM-11 in the
final stages of development," said Dr. Andrew Cavey, "and I look forward to
working with the entire ITM team to deliver on the company's exceptional
potential."
Dr. Cavey will join ITM from his most recent position as SVP, Head of Global
Program Leaders, Hematology, Oncology, Cell Therapy at BMS, where he helped the
company enter into radiopharmaceuticals. Before this, he held several leadership
positions at Novartis over the course of eleven years, culminating in his role
as Global Program Head, Prostate Cancer, in which he co-led the company's
Radiopharmaceutical Therapy strategy and led teams overseeing the regulatory
approvals of Pluvicto® and Locametz® in the US and Europe. Dr. Cavey holds his
physiological sciences and medical degrees from Oxford University, and a
Master's in Public Health from Harvard University. He gained membership to the
UK Royal College of Physicians and currently serves as a Board Trustee for
Parkinson's UK.
"With his experience spearheading pipeline and commercial operations while
implementing corporate strategies, I fully support Andrew's appointment to CEO
as the right step for ITM's growth. It has been an honor to guide this
organization over the past decade, and I look forward to contributing to its
continued progress," commented Steffen Schuster, CEO of ITM.
About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a
new generation of radiomolecular precision therapeutics and diagnostics for
hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians
and our partners through excellence in development, production and global
supply. With improved patient benefit as the driving principle for all we do,
ITM advances a broad precision oncology pipeline, including two phase III
studies, combining the company's high-quality radioisotopes with a range of
targeting molecules. By leveraging our nearly two decades of pioneering
radiopharma expertise, central industry position and established global network,
ITM strives to provide patients with more effective targeted treatment to
improve clinical outcome and quality of life. www.itm-radiopharma.com
(http://www.itm-radiopharma.com)
ITM Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email: communications@itm-radiopharma.com (mailto:communications@itm-
radiopharma.com)
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com (mailto:investors@itm-radiopharma.com)
(mailto:investors@itm-radiopharma.com)
(mailto:investors@itm-radiopharma.com)
Â